, Tracking Stock Market Picks
Enter Symbol:
NovaBay Pharmaceuticals Inc. (NBY) [hlAlert]

Strong Buy
down 67.76 %

NovaBay Pharmaceuticals Inc. (NBY) rated Strong Buy with price target $2.25 by Ascendiant Capital Markets

Posted on: Wednesday,  Mar 6, 2013  8:25 AM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Strong Buy NovaBay Pharmaceuticals Inc. (AMEX: NBY) on 03/06/2013, when the stock price was $1.21.
Since then, NovaBay Pharmaceuticals Inc. has lost 67.77% as of 08/27/2015's recent price of $0.39.
If you would have followed this Ascendiant Capital Markets's recommendation on NBY, you would have lost 67.76% of your investment in 904 days.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage biopharmaceutical company developing synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments. The Company?s Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are effective and acting anti-infective molecules produced by white blood cells when defending the body against invading pathogens. In preclinical testing, its Aganocide compounds have demonstrated the ability to destroy bacteria, against which they have been tested. On March 25, 2009, the Company announced that it had entered into an agreement with Galderma S.A. to develop and commercialize its Aganocide compounds.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2013 8:25 AM Buy
1.21 2.25
as of 12/13/2013
1 Week down  -9.35 %
1 Month up  21.15 %
3 Months down  -8.69 %
1 YTD up  4.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy